CD19x22 CAR T cells

CD19x22 CAR T cells are autologous chimeric antigen receptor (CAR) T cell therapies engineered to co-express two distinct receptors targeting both the B-cell antigens CD19 and CD22. This dual-targeting approach is designed to overcome resistance mechanisms such as antigen escape that can occur with single-antigen targeting therapies. The therapy uses a bicistronic construct allowing simultaneous expression of a CAR against CD19 (incorporating a CD28 costimulatory domain) and a separate CAR against CD22 (incorporating a 4-1BB costimulatory domain), enhancing anti-tumor efficacy by enabling the modified T-cells to recognize and kill tumor cells expressing either or both antigens. Preclinical studies have shown activity against both acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL), with clinical trials ongoing in relapsed/refractory B-cell malignancies[1][2][3][5].

Other names

CD19x22 bicistronic CAR T cellsCD-19x22 bicistronic CAR T cellsCD 19x22 bicistronic CAR T cells